Haemonetics (HAE) 주식 개요
의료 기술 회사인 해모네틱스는 미국 및 전 세계에 병원 기술 솔루션 제품군을 제공합니다. 자세히 보기
HAE Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Haemonetics Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$59.56 |
| 52주 최고가 | US$87.32 |
| 52주 최저가 | US$47.32 |
| 베타 | 0.53 |
| 1개월 변동 | -2.63% |
| 3개월 변동 | -1.83% |
| 1년 변동 | -11.00% |
| 3년 변동 | -28.52% |
| 5년 변동 | 7.37% |
| IPO 이후 변동 | 903.12% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 09
HAE: New Approvals And Trials Will Support Upside Despite Cautious Repricing
Haemonetics' updated analyst price target reflects a modest reset in expectations, with several firms trimming their targets by $4 to $12 as analysts factor in slightly lower revenue growth assumptions, a marginally higher profit margin outlook, and a small adjustment to the assumed future P/E multiple. Analyst Commentary Recent research shows a cluster of bearish adjustments to Haemonetics' price targets, with several bearish analysts trimming their numbers in close succession.내러티브 업데이트 • Apr 22
HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing
Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.
내러티브 업데이트 • Apr 08
HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing
Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.Recent updates
내러티브 업데이트 • May 09
HAE: New Approvals And Trials Will Support Upside Despite Cautious Repricing
Haemonetics' updated analyst price target reflects a modest reset in expectations, with several firms trimming their targets by $4 to $12 as analysts factor in slightly lower revenue growth assumptions, a marginally higher profit margin outlook, and a small adjustment to the assumed future P/E multiple. Analyst Commentary Recent research shows a cluster of bearish adjustments to Haemonetics' price targets, with several bearish analysts trimming their numbers in close succession.내러티브 업데이트 • Apr 22
HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing
Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.내러티브 업데이트 • Apr 08
HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing
Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.내러티브 업데이트 • Mar 25
HAE: Vivasure Deal And Pipeline Progress Will Support Future Share Recovery
Analysts have reduced the Haemonetics fair value estimate to $70 from $74. Recent target resets in the group, including Citi's move to $70, reflect updated assumptions around growth, margins and the P/E multiple for the stock.내러티브 업데이트 • Mar 10
HAE: Vivasure Deal And 2026 Outlook Will Support Earnings Quality
Analysts have modestly adjusted their views on Haemonetics, with several firms trimming price targets by $10 to $18 and one small $1 upward revision. These changes reflect updated assumptions on valuation multiples, while fair value and key model inputs remain broadly unchanged.내러티브 업데이트 • Feb 23
HAE: Vivasure Acquisition And FY26 Outlook Will Support Margin Recovery
The analyst price target for Haemonetics has been reduced by $3.70, with analysts pointing to a slightly higher discount rate, a lower fair value estimate and some pressure on projected profit margins, even as they continue to apply a higher forward P/E and updated revenue growth assumptions in their models. Analyst Commentary Recent Street research on Haemonetics has been mixed, with several firms trimming their price targets while at least one firm has lifted its target in connection with the Vivasure Medical acquisition.내러티브 업데이트 • Feb 08
HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery
Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition. Analyst Commentary Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition.내러티브 업데이트 • Jan 25
HAE: Vivasure Deal And Buyback Will Shape Execution And Share Recovery
Analysts have lifted their price target for Haemonetics from about $58 to roughly $74.82, citing recent Street research that points to higher assumed revenue growth, slightly stronger profit margins, a higher future P/E, and supportive views on the Vivasure acquisition and recent earnings execution. Analyst Commentary Recent Street research has centered on two main themes for Haemonetics, the Vivasure acquisition and the company’s latest earnings print.Seeking Alpha • Jan 11
Haemonetics: Re-Rating Complete, Time To Cash In
Summary Haemonetics has rebounded sharply, with shares up 50% in under six months following a modest organic growth guidance hike. Haemonetics' re-rating is now largely complete, as valuation stands at 17x adjusted earnings and low-20s on free cash flow multiples. Recent guidance improvements are mainly currency-driven, with organic growth momentum excluding CSL showing underlying strength. I am turning cautious and actively trimming my position, as shares now appear fairly valued after rapid appreciation. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 11
HAE: Achievable Hospital Reset And FY26 Outlook Will Support Gradual Recovery
Narrative Update on Haemonetics Analysts have inched up their price target for Haemonetics, with updated fair value rising from about US$90 to roughly US$92, citing recent price target increases, company performance that met or exceeded expectations across segments, and what they view as more achievable guidance and improved credibility on execution and messaging. Analyst Commentary Recent commentary has focused on how Haemonetics is executing against expectations, how realistic its guidance looks, and what that might mean for valuation support and potential growth in the medium term.분석 기사 • Jan 06
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...내러티브 업데이트 • Dec 24
HAE: Achievable Hospital Guidance Reset Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $90 from about $86, citing stronger than expected execution across all segments, a more achievable Hospital guidance reset, and an improved long term sales outlook that supports higher growth and valuation assumptions. Analyst Commentary Analysts see the recent quarter as a constructive inflection point for Haemonetics, with improved guidance and execution supporting a modestly higher valuation framework, though some caution remains around sustainability of growth and delivery against new targets.내러티브 업데이트 • Dec 10
HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.내러티브 업데이트 • Nov 26
HAE: Solid Execution And Achievable Guidance Will Support Measured Share Recovery
Analysts have raised their price target for Haemonetics from $83 to approximately $84.55. They cite solid execution, an improved sales outlook, and increased confidence in the company's guidance and operational credibility.내러티브 업데이트 • Nov 12
HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery
Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.분석 기사 • Nov 07
A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Haemonetics Corporation ( NYSE:HAE ) shares have had a really impressive month, gaining 36% after a shaky period...내러티브 업데이트 • Oct 28
Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion
Haemonetics’ analyst price target has been revised lower by analysts to approximately $76 from $77. This change reflects concerns about execution within the Interventional Technologies segment, despite confidence in the company’s long-term value.내러티브 업데이트 • Oct 14
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.분석 기사 • Sep 15
Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haemonetics fair value estimate is US$100 Haemonetics...내러티브 업데이트 • Aug 08
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.분석 기사 • Aug 08
Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower
Haemonetics Corporation ( NYSE:HAE ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Jun 30
Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jun 10
Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings
Haemonetics Corporation's ( NYSE:HAE ) price-to-earnings (or "P/E") ratio of 20.5x might make it look like a sell right...분석 기사 • May 10
Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Mar 18
Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Feb 20
Haemonetics: Almost Blood In The Streets
Summary Haemonetics shares have been trading at more appealing levels after a reduction in full-year sales guidance, trading at historically reasonable levels. The company, generating $1.3 billion in annual sales, has seen modest growth, with significant contributions from its plasma and hospital segments. Despite a cautious outlook due to suboptimal positioning in some units, Haemonetics aims for continued growth in 2025, aided by M&A efforts. Shares have fallen to $64, valuing the business at 3 times sales, with adjusted earnings multiples dropping to mid-teens multiple. The appeal is improving here. Read the full article on Seeking Alpha분석 기사 • Feb 13
Haemonetics (NYSE:HAE) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Haemonetics Corporation ( NYSE:HAE ) recently. Our...분석 기사 • Dec 06
Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings
Haemonetics Corporation's ( NYSE:HAE ) price-to-earnings (or "P/E") ratio of 32.7x might make it look like a strong...분석 기사 • Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
새로운 내러티브 • Sep 03
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.분석 기사 • Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...분석 기사 • Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Key Insights The projected fair value for Haemonetics is US$167 based on 2 Stage Free Cash Flow to Equity Haemonetics...Seeking Alpha • Jun 21
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100. Read the full article on Seeking Alpha분석 기사 • Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 34.7x Haemonetics Corporation ( NYSE:HAE ) may be sending very bearish...분석 기사 • Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Key Insights Haemonetics' estimated fair value is US$120 based on 2 Stage Free Cash Flow to Equity Haemonetics...Seeking Alpha • Mar 06
Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Summary Haemonetics Corporation has announced a $160 million cash deal to acquire Attune Medical, a manufacturer of esophageal cooling devices. Haemonetics has seen improvements in its business after a tough period during the pandemic, but its share price has lagged. The company's adjusted earnings multiples have fallen below 20 times, making its shares more reasonably priced. Read the full article on Seeking Alpha분석 기사 • Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Haemonetics Corporation ( NYSE:HAE ) just reported healthy earnings but the stock price didn't move much. Investors are...분석 기사 • Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Seeking Alpha • Nov 22
Haemonetics: Solid Performance Of This Blood Play
Summary Haemonetics has seen signs of growth and operational momentum after a challenging period during the pandemic. The company's fiscal year 2024 first half results were solid, increasing its appeal. Still trading at a small premium based on adjusted earnings, valuations remain somewhat demanding despite arguably a solid operating performance year to date. Read the full article on Seeking Alpha분석 기사 • Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...주주 수익률
| HAE | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 4.5% | 2.9% | -1.0% |
| 1Y | -11.0% | -21.1% | 23.3% |
수익률 대 산업: HAE은 지난 1년 동안 -21.1%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: HAE은 지난 1년 동안 23.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| HAE volatility | |
|---|---|
| HAE Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: HAE는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: HAE의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1971 | 3,023 | Chris Simon | www.haemonetics.com |
의료 기술 회사인 해모네틱스는 미국과 전 세계에 병원 기술 솔루션 제품군을 제공합니다. 이 회사는 자동화된 혈장 채집 시스템, 기증자 관리 소프트웨어, 지원 소프트웨어 솔루션(NexSys PCS 및 PCS2 혈장 분리 장비와 관련 일회용품 및 솔루션, 기증자, 운영 및 공급망 관리를 위한 통합 정보 기술 플랫폼, NexLynk DMS 기증자 관리 시스템 및 Donor360 도구 포함)을 제공합니다. 또한 전기생리학, 중환자 치료, 신경 중환자 치료, 외상, 화상 수술, 척추 수술, 암 수술, TAVR 시술용 센서 유도 3-in-1 가이드 와이어인 SavvyWire, 분획 유량 예비 및 이완기 압력비를 측정하는 압력 가이드 와이어인 OptoWire, 의료 기기 및 기타 중요한 산업 응용 분야에 사용되는 광섬유 센서 솔루션도 제공합니다.
Haemonetics Corporation 기초 지표 요약
| HAE 기초 통계 | |
|---|---|
| 시가총액 | US$2.64b |
| 순이익 (TTM) | US$97.31m |
| 매출 (TTM) | US$1.33b |
28.4x
주가수익비율(P/E)2.1x
주가매출비율(P/S)HAE는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| HAE 손익계산서 (TTM) | |
|---|---|
| 매출 | US$1.33b |
| 매출원가 | US$537.45m |
| 총이익 | US$796.58m |
| 기타 비용 | US$699.27m |
| 순이익 | US$97.31m |
최근 보고된 실적
Mar 28, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 2.09 |
| 총이익률 | 59.71% |
| 순이익률 | 7.29% |
| 부채/자본 비율 | 153.8% |
HAE의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 03:40 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/28 |
| 연간 수익 | 2026/03/28 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Haemonetics Corporation는 25명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |
| Raymond Myers | Benchmark Company |